ClinicalTrials.Veeva

Menu

A Serosurvey Study of Hand, Foot, and Mouth Disease in Indonesia

Sinovac logo

Sinovac

Status

Completed

Conditions

Hand, Foot and Mouth Disease

Study type

Observational

Funder types

Industry

Identifiers

NCT05637229
PRO-EV71-4101

Details and patient eligibility

About

This study is a sero-survey study of infants aged 6 months to 71 months in Bandung City and West Bandung District. As initial data to find out how many children have been exposed to human enterovirus type 71 (HEV-71) which causes Hand, foot, and mouth disease (HFMD).

Full description

This study is a cross-sectional seroprevalence survey of EV-71, associated with HFMD, among children aged between 6 to 71 months in Bandung, sampled from urban and rural Primary Health Center in Bandung, Indonesia. This study was implemented by Department of Child Health Hasan Sadikin General Hospital/Medical Faculty Universitas Padjadjaran Bandung, West Java. Age-stratified sample of 600 children aged 6-71 months will be conducted from these sites. Samples testing includes routine blood counts, enzyme-linked immunosorbent assays (ELISAs) for enterovirus type 71 (EV71) IgG and ELISAs for other HFMD-associated enteroviruses.

Enrollment

600 patients

Sex

All

Ages

6 to 71 months old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Children aged 6 months to 71 months.
  • The participant's parent/guardian receives an explanation and receives a Letter of Consent after the explanation (informed consent) and provided a documented informed consent by parents/legally accepted representative (LAR) participants prior to the study procedures.
  • Domicile in Bandung and West Bandung District for at least 6 months.

Exclusion criteria

  • Children with difficulty to withdraw the blood during blood collection
  • Children with severe illness who require further treatment

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems